ESC 365 - Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden

ESC Premium Access

Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden

Session: How good/bad are we in treating lipids

Topic: Drug therapy

Speaker: Associate Professor E. Hagstrom (Uppsala, SE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Associate Professor Emil Hagstrom

Uppsala University, Uppsala (Sweden)

1 presentation

0 follower

6 more presentations in this session

Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort

Speaker: Doctor B. Gencer (Lausanne, CH)

Attributable risk proportion of uncontrolled low-density lipoprotein cholesterol in recurrent acute coronary syndromes

Speaker: Doctor E. Martinez Rey-Ranal (Elche, ES)

Statin treatment in children with familial hypercholesterolemia in Scandinavia

Speaker: Doctor K. Svendsen (Oslo, NO)

Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES

Speaker: Professor G. Schwartz (Aurora, US)

Remnant lipoprotein is a residual risk of future cardiovascular events in patients with stable coronary artery disease and on statin LDL-cholesterol levels less than 70 mg/dl

Speaker: Doctor Y. Fujihara (Kofu, JP)

Access the full session

How good/bad are we in treating lipids

Speakers: Associate Professor E. Hagstrom, Doctor B. Gencer, Doctor E. Martinez Rey-Ranal, Doctor K. Svendsen, Professor G. Schwartz...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources